PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Cagrilintide

AM833; NN9838

Classification: Long-acting amylin analog

Mechanism: Amylin receptor agonist; delays gastric emptying; enhances satiety

Benefits: Appetite suppression; weight loss ~10% monotherapy; synergy with semaglutide

Evidence tier: Phase 2/3 · Availability: Investigational

Primary sources

  1. Lau DCW et al. Once-weekly cagrilintide for weight management — multicentre, randomised, double-blind, dose-finding phase 2 trial. Lancet 2021. PMID 34798060
  2. Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with semaglutide 2.4 mg — phase 1b trial. Lancet 2021. PMID 33894838

Loading interactive view…